FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileVeradermics, Incorporated
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MANE
Veradermics, Incorporated Stock AnalysisComprehensive stock analysis for Veradermics, Incorporated (MANE) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMANE
MANE
Veradermics, Incorporated
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MANE
  1. Home
  2. Stocks
  3. Veradermics, Incorporated

Veradermics, Incorporated

🇺🇸MANE•NYSE

Veradermics, Incorporated

🇺🇸MANE•NYSE
Market cap
$5.27B

Your view on MANE

Mkt Cap
$5.27B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Veradermics, Incorporated

Industry
Biotechnology
Sector
Healthcare
CEO
Reid Waldman
Headquarters
470 James Street, New Haven, CT, US
Industry
Biotechnology
Sector
Healthcare
CEO
Reid Waldman
Headquarters
470 James Street, New Haven, CT, US
Description

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics.

A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts.

Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis.

Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Veradermics, Incorporated. Starting points for Veradermics, Incorporated: EPS -$2.22, beta 1.23 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Veradermics, Incorporated. Trailing twelve-month EPS for Veradermics, Incorporated stands at -$2.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$174.00

average of 3 firms, last 12 months

 

$174.00

Low $136.00

Median $182.00

High $204.00

 

Analyst Ratings

Buy6 firms, last 12 months
  • Strong Buy0
  • Buy6
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate−$0.61−$0.60−$2.72−$2.66
Low estimate−$0.61−$0.60−$11.48−$11.22
High estimate−$0.61−$0.60−$0.22−$0.21
No. of analysts3134
Year-ago EPS−$1.63−$1.321−$111.911—
Growth+62.3%———

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$0.00$12.47M
Low estimate$0.00$0.00$0.00$3.64M
High estimate$0.00$0.00$0.00$43.32M
No. of analysts0006
Year-ago revenue$0.00$0.00$0.00—
Growth————
Recent analyst actions14 rating and price-target changes, latest Nov 10, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Veradermics, Incorporated. Veradermics, Incorporated has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MANE19 companies · 8 funds
Compare MANE with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ABEOAbeona Therapeutics Inc.HealthcareBiotechnology$156.0M
ADILAdial Pharmaceuticals, Inc.HealthcareBiotechnology$13.3M
DRMADermata Therapeutics, Inc.HealthcareBiotechnology$2.7M
HELPCybin Inc. Common StockHealthcareMedical - Pharmaceuticals$427.1M
LSTALisata Therapeutics, Inc.HealthcareBiotechnology$8.8M
OVIDOvid Therapeutics Inc.HealthcareBiotechnology$426.5M
PLYXPolaryx Therapeutics, Inc. Common StockHealthcareBiotechnology$80.3M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ZLDAFZelira Therapeutics LimitedHealthcareOTC$5.0M
ZLDPFZealand Pharma A/SHealthcareOTC$4.0B
ZNTLZentalis Pharmaceuticals, Inc.HealthcareNASDAQ$133.6M
ZURAZura Bio LimitedHealthcareNASDAQ$93.0M
ZVRAZevra Therapeutics, Inc.HealthcareNASDAQ$552.2M
ZVSAZyVersa Therapeutics, Inc.HealthcareOTC$1.1M
ZYMEZymeworks Inc.HealthcareNASDAQ$1.8B
VSBCVitaSpring Biomedical Co. Ltd.HealthcareOTC$2.3M
VSTMVerastem, Inc.HealthcareNASDAQ$865.7M
VTGNVistaGen Therapeutics, Inc.HealthcareNASDAQ$9.2M
VTIAFFamiCord AGHealthcareOTC$111.1M
VTVTvTv Therapeutics Inc.HealthcareNASDAQ$64.2M
ETFs holding Veradermics, Incorporated
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
IWMiShares Russell 2000 ETF$76.6B in assets0.10%
XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged)$627M in assets0.10%
VXFVanguard Extended Market ETF$30.2B in assets0.05%
LFSCF/M Emerald Life Sciences Innovation ETF$125M in assets3.87%
SBIOALPS Medical Breakthroughs ETF$187M in assets3.61%
TOSThe RBB Fund Trust - Twin Oak Strategic Solutions ETF$146M in assets2.81%
XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets2.66%

Largest holders first, then the funds most concentrated in MANE.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Veradermics, Incorporated, and how their positions are changing. At a $5.27B market value, institutional positions materially move Veradermics, Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Veradermics, Incorporated executives and directors. Shares of Veradermics, Incorporated have traded between $32.00 and $131.24 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Veradermics, Incorporated. Coverage tracks Veradermics, Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Veradermics, Incorporated.

MANE AnalysisFair
Past
5
Growth
2
Health
5
Profit
1
Value
1

News

Latest Market News